Background/Objectives: The incidence of Ceftazidime/Avibactam (CZA)-resistant Klebsiella pneumoniae isolate co-producing Klebsiella pneumoniae carbapenemase 2 (KPC-2) and Vietnamese extended-spectrum β-lactamase 25 (VEB-25) has been on the rise in Greece over the past five years. This study investigates the isolation of ST323 K. pneumoniae isolates co-resistant to CZA and cefiderocol (FDC) from colonized and infected patients in a single hospital in Athens. Methods: CZA-resistant K. pneumoniae strains were isolated from 5 ICU patients from 27 December 2023 to 22 January 2024. Antimicrobial susceptibility was tested against a panel of agents. Whole-genome sequencing of the isolates was carried out to identify the acquired resistance genes and mutations that were associated with CZA and FDC resistance. Results: The K. pneumoniae isolates belonged to ST323 and harbored blaKPC-2 and blaVEB-25. The isolates had a minimum inhibitory concentration (MIC) of >256 mg/L for CZA and 32 mg/L for FDC, due to the disrupted catecholate siderophore receptor Fiu. blaVEB-25 was located on an IncC non-conjugative plasmid and on a ~14 kb multidrug resistance (MDR) region comprising 15 further acquired resistance genes. Transformation studies showed that the blaVEB-25-carrying plasmid provided resistance to most of the β-lactams tested, including CZA. The isolates remained susceptible to carbapenems, imipenem/relebactam, and meropenem/vaborbactam. The plasmid harbored the citrate-dependent iron (III) uptake system (fecIRABCDE), which increased the MIC of FDC from ≤0.08 mg/L to 2 mg/L. Conclusions: The blaVEB-25 gene was associated with IncC plasmids which are important contributors to the spread of key antibiotic resistance genes. Strict infection control measures must be elaborated upon to prevent the spread of extensively drug-resistant organisms such as those described here.
Background/Objectives: Candidozyma auris (C. auris) is a multidrug-resistant pathogen recognized as a serious global public health threat. Herein, we report a C. auris outbreak that was successfully contained in a general hospital located in Athens, Greece. Methods: This study was conducted between December 2021 and December 2023. Upon identification of the first imported case of C. auris, the following infection control measures were applied in a stepwise approach: the promotion of hand hygiene, contact precautions and isolation, chlorhexidine gluconate bathing of patients, enhanced environmental cleaning, and active surveillance cultures of all high-risk patients upon admission. Active surveillance cultures were performed weekly in non-colonized ICU patients. Results: A total of 1564 screening samples from 890 patients were analyzed. Sixty-three patients were identified to be colonized and three to be infected with C. auris. After implementing screening and enhanced environmental cleaning, the quarterly incidence of hospital-acquired cases decreased from 0.37 to 0.04 cases per 1000 patient-days (slope of linear trend: −0.08; 95% CI: −0.16 to −0.0004; p = 0.05), despite the continuous inflow of already colonized patients. Conclusions: A bundle of infection control measures, including active surveillance cultures upon admission and enhanced environmental cleaning, can contain C. auris dissemination in acute healthcare settings.